SENSORCAINE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Sensorcaine, and when can generic versions of Sensorcaine launch?
Sensorcaine is a drug marketed by Fresenius Kabi Usa and is included in eight NDAs.
The generic ingredient in SENSORCAINE is bupivacaine hydrochloride. There are twelve drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the bupivacaine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sensorcaine
A generic version of SENSORCAINE was approved as bupivacaine hydrochloride by HOSPIRA on February 17th, 1986.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SENSORCAINE?
- What are the global sales for SENSORCAINE?
- What is Average Wholesale Price for SENSORCAINE?
Summary for SENSORCAINE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 8 |
Finished Product Suppliers / Packagers: | 4 |
Raw Ingredient (Bulk) Api Vendors: | 124 |
Clinical Trials: | 26 |
Patent Applications: | 4,792 |
Drug Prices: | Drug price information for SENSORCAINE |
What excipients (inactive ingredients) are in SENSORCAINE? | SENSORCAINE excipients list |
DailyMed Link: | SENSORCAINE at DailyMed |
Recent Clinical Trials for SENSORCAINE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
The University of Hong Kong | Phase 3 |
Christopher Connors, MD | Phase 4 |
Case Comprehensive Cancer Center | Phase 2 |
Pharmacology for SENSORCAINE
Drug Class | Amide Local Anesthetic Catecholamine alpha-Adrenergic Agonist beta-Adrenergic Agonist |
Mechanism of Action | Adrenergic alpha-Agonists Adrenergic beta-Agonists |
Physiological Effect | Local Anesthesia |